SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-190492
Filing Date
2022-07-08
Accepted
2022-07-08 16:13:04
Documents
20
Period of Report
2022-07-07
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d355546d8k.htm   iXBRL 8-K 34672
2 EX-4.1 d355546dex41.htm EX-4.1 61751
3 EX-5.1 d355546dex51.htm EX-5.1 13785
4 EX-10.1 d355546dex101.htm EX-10.1 157425
5 EX-99.1 d355546dex991.htm EX-99.1 8981
6 EX-99.2 d355546dex992.htm EX-99.2 9013
10 GRAPHIC g355546g0707075029585.jpg GRAPHIC 3993
11 GRAPHIC g355546g0707075609747.jpg GRAPHIC 2899
12 GRAPHIC g355546g0708083243290.jpg GRAPHIC 2907
  Complete submission text file 0001193125-22-190492.txt   504200

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA nrix-20220707.xsd EX-101.SCH 2856
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrix-20220707_lab.xml EX-101.LAB 17994
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrix-20220707_pre.xml EX-101.PRE 11261
14 EXTRACTED XBRL INSTANCE DOCUMENT d355546d8k_htm.xml XML 3356
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

IRS No.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 8-K | Act: 34 | File No.: 001-39398 | Film No.: 221074540
SIC: 2834 Pharmaceutical Preparations